Update Breast Cancer 2022 Part 1 - Early Stage Breast Cancer

Manfred Welslau, Volkmar Müller, Diana Lüftner, Florian Schütz, Elmar Stickeler, Peter A Fasching, Wolfgang Janni, Christoph Thomssen, Isabell Witzel, Tanja N Fehm, Erik Belleville, Simon Bader, Katharina Seitz, Michael Untch, Marc Thill, Hans Tesch, Nina Ditsch, Michael P Lux, Bahriye Aktas, Maggie Banys-PaluchowskiAndreas Schneeweiss, Nadia Harbeck, Rachel Würstlein, Andreas D Hartkopf, Achim Wöckel, Barbara Seliger, Chiara Massa, Hans-Christian Kolberg


Evidence relating to the treatment of breast cancer patients with early-stage disease has increased significantly in the past year. Abemaciclib, olaparib, and pembrolizumab are new drugs with good efficacy in the relevant patient groups. However, some questions remain unanswered. In particular, it remains unclear which premenopausal patients with hormone receptor-positive breast cancer should be spared unnecessary treatment. The question of the degree to which chemotherapy exerts a direct cytotoxic effect on the tumor or reduces ovarian function through chemotherapy could be of key importance. This group of patients could potentially be spared chemotherapy. New, previously experimental biomarker analysis methods, such as spatial analysis of gene expression (spatial transcriptomics) are gradually finding their way into large randomized phase III trials, such as the NeoTRIP trial. This in turn leads to a better understanding of the predictive factors of new therapies, for example immunotherapy. This review summarizes the scientific innovations from recent congresses such as the San Antonio Breast Cancer Symposium 2021 but also from recent publications.

Original languageEnglish
JournalGeburtshilfe und Frauenheilkunde
Issue number6
Pages (from-to)580-589
Number of pages10
Publication statusPublished - 06.2022

Research Areas and Centers

  • Centers: University Cancer Center Schleswig-Holstein (UCCSH)
  • Research Area: Luebeck Integrated Oncology Network (LION)


Dive into the research topics of 'Update Breast Cancer 2022 Part 1 - Early Stage Breast Cancer'. Together they form a unique fingerprint.

Cite this